(UroToday.com) At the 2021 American Urologic Association (AUA) annual meeting, Dr. Michael Fabrizio discussed real-world utilization of apalutamide and enzalutamide in non-metastatic castrate resistant prostate cancer. Management of non-metastatic castrate-resistant prostate cancer has shifted since the approval of three second-generation androgen receptor antagonists: apalutamide, enzalutamide, and darolutamide. In clinical trials, all agents have proven to delay metastases, with discontinuation rates due to adverse events in 15% of apalutamide patients, 17% of enzalutamide patients, an 9% of darolutamide patients.1-3 However, real-world data on these agents is lacking. Dr. Fabrizio and colleagues aimed to assess the real-world utilization of two of these new agents (apalutamide and enzalutamide) among non-metastatic castrate-resistant prostate cancer patients from urology electronic medical records database.